PharmaShots | Incisive News in 3 Shots

Subscribe Now

Exacis

Exacis Entered into an Option to License Agreement with Eterna for Four iPSC Derived NK Cell and T Cell Therapies

Exacis Entered into an Option to License Agreement with Eterna for Four iPSC Derived NK Cell and T Cell Therapies

October 18, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us